Rachid Izzar - 02 Dec 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
Head of Alzheimer's Disease
Signature
/s/ Wendell Taylor, attorney-in-fact for Rachid Izzar
Issuer symbol
BIIB
Transactions as of
02 Dec 2022
Transactions value $
$-226,865
Form type
4
Filing time
06 Dec 2022, 17:37:53 UTC
Previous filing
06 Jul 2022
Next filing
27 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +1,285 +60.9% $0.000000 3,395 02 Dec 2022 Direct
transaction BIIB Common Stock Tax liability $-170,373 -570 -16.8% $298.90 2,825 02 Dec 2022 Direct
transaction BIIB Common Stock Options Exercise $0 +425 +15% $0.000000 3,250 02 Dec 2022 Direct
transaction BIIB Common Stock Tax liability $-56,492 -189 -5.82% $298.90 3,061 02 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Options Exercise $0 -1,285 -100% $0.000000* 0 02 Dec 2022 Common Stock 1,285 $0.000000 Direct F1
transaction BIIB Restricted Stock Unit Options Exercise $0 -425 -49.5% $0.000000 433 02 Dec 2022 Common Stock 425 $0.000000 Direct F2
transaction BIIB Restricted Stock Unit Other $0 -433 -100% $0.000000* 0 02 Dec 2022 Common Stock 433 $0.000000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award was granted to the reporting person on December 2, 2019, and vested in full on December 2, 2022.
F2 This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F3 This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.